Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma

Abstract

Purpose: Although the prognostic value of B7-H1and B7-H4 expression by tumor cells in clear cell renal cell carcinoma (ccRCC) has been established, the role of B7-H3 is unknown. As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC. Experimental Design: Nephrectomy specimens from 743 consecutive patients treated for ccRCC at our institution from 1990 to 1999 were evaluated for B7-H3 expression by immunohistochemical staining. Associations of B7-H3 expression with clinical and pathologic features were evaluated using m 2 and Fisher's exact tests. Associations of B7-H3 expression with death from RCC were evaluated using Cox proportional hazards regression models. Results: B7-H3 expression by tumor cells or tumor vasculature was noted in 17% and 95% of specimens, respectively. The presence of either tumor cell or diffuse tumor vasculature expression of B7-H3 was present in 46% of specimens and was associated with multiple adverse clinical and pathologic features. After multivariable adjustment, the presence of either tumor cell or diffuse tumor vasculature B7-H3 expression was significantly associated with an increased risk of death from RCC (risk ratio, 1.38; 95 % confidence interval, 1.03-1.84; P = 0.029). Conclusions: Both tumor cell and tumor vasculature B7-H3 expression convey important information to predict ccRCC outcomes. Collectively, our past and present studies pertaining to B7-H ligand expression indicate that ccRCC may use redundant mechanisms to compromise host antitumoral immunity. Future studies will focus on the effect of combined B7-H ligand expression in RCC.

B7‐H3 expression in gastric cancer: A novel molecular blood marker for detecting circulating tumor cells

“…B7-H3 is not unique to gastric tumor cells and it is expressed in other malignancies. (23)(24)(25)(26)30,31) Therefore, B7-H3 might serve as a tumor marker of various malignancies.…”

“…(23,25,26) However, little is understood about the clinical significance of B7-H3 mRNA expression in blood specimens from patients with gastric cancer.…”

“…(22) Immunohistochemistry has confirmed B7-H3 protein expression in prostate, non-small cell lung, gastric and clear cell renal cell cancers. (23)(24)(25)(26) B7-H3 expression in tumor cells is closely correlated with tumor progression in these malignancies. (23,25,26) However, little is understood about the clinical significance of B7-H3 mRNA expression in blood specimens from patients with gastric cancer.…”

Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response

“…found in a variety of different human cancers, including prostate (19,20), nonsmall cell lung (NSCLC) (21), gastric (22,23), pancreatic (24), ovarian (25), colorectal (26), urothelial cell (27), clear cell renal cell (ccRCC) (28), and hypopharyngeal (29) cancers.…”

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

“…Moreover, some molecules (CD70, HLA-G, PD-L1, B7-H3, B7-H4) are expressed at higher frequencies in RCC, thereby further affecting the phenotype of CD8 C TIL in RCC compared to other tumors. [32][33][34] State of the art of cancer immunotherapy in RCC Currently, recombinant cytokines are the only approved immunotherapies for RCC. The potential of other types of cancer immunotherapy is, however, evidenced by the effectiveness of the cancer vaccine sipuleucel-T in prostate cancer.…”